Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential
5 affiliations
- 1Department of Emergency Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
- 2Clinical Research Development Unit, Ghaem Hospital Mashhad University of Medical Sciences Mashhad Iran
- 3School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran
- 4Pharmacological Research Center of Medicinal Plants, Basic Sciences Research Institute Mashhad University of Medical Sciences Mashhad Iran
- 5Shahid Hasheminejad Hospital, Mashhad University of Medical Sciences Mashhad Iran
Abstract
Osteoporosis is a chronic bone disease marked by reduced density and increased fracture risk. Current treatments face limitations in safety, efficacy, and long‐term adherence, prompting interest in alternative therapies. Herbal medicine, with its bioactive compounds and historical use, offers potential for bone health support. This review explores the role of Chrysanthemum morifolium , Crocus sativus , Eriobotrya japonica , Ficus carica , Glycine max , Olea europaea , Salvia rosmarinus , and Zingiber officinale in preventing and managing osteoporosis. Relevant studies were identified through comprehensive searches of Google Scholar, PubMed, Scopus, and Web of Science, without time restriction up to October 2025. Included literature encompassed in vitro experiments, in vivo animal models, and clinical trials investigating herbal interventions targeting bone loss and osteoporosis‐related mechanisms. The reviewed botanicals modulate key molecular pathways involved in bone remodeling, including RANKL/NFATc1, MAPKs, NF‐κB, Sirt1, Nrf2, BMP/Smad, Wnt/β‐catenin, and XPO5–microRNA axes. Their bioactive constituents exert antioxidant, anti‐inflammatory, anti‐apoptotic, anti‐senescent, and hormone‐modulating effects, collectively promoting osteoblast differentiation and suppressing osteoclastogenesis. Several agents, such as crocin, safranal, and ursolic acid, demonstrated dual‐action profiles and favorable safety in preclinical models, with emerging evidence supporting their immunomodulatory and angiogenic roles. Herbal therapeutics offer a multi‐targeted, biologically harmonious approach to osteoporosis management. This review provides a mechanistic synthesis and translational framework for future research, highlighting their potential as adjunctive therapies, especially in aging populations. Standardization, clinical validation, and interdisciplinary collaboration are essential to advance these botanicals from bench to bedside.
Related
- The gut–bone axis in osteoporosis: microbial mechanisms, conflicting evidence, and translational priorities
- Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges
- AI-guided design and biomaterial integration for next-generation extracellular vesicle therapeutics: an evidence-weighted translational framework.
- Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics
- Microbiome-derived Metabolites in Anti-inflammatory Therapy: from Mechanisms to Translational Potential
BibTeX
@article{moradi2026herbal,
title = {{Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential}},
author = {Elnaz Vafadar Moradi and Sina Vossoughinia and Zahra Yazdanpanah and Hossein Sobhani and Jalileh Jalali and Mahboobeh Ghasemzadeh Rahbardar},
journal = {Phytotherapy Research},
year = {2026},
month = sep,
doi = {10.1002/ptr.70457},
url = {https://doi.org/10.1002/ptr.70457},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential
AU - Elnaz Vafadar Moradi
AU - Sina Vossoughinia
AU - Zahra Yazdanpanah
AU - Hossein Sobhani
AU - Jalileh Jalali
AU - Mahboobeh Ghasemzadeh Rahbardar
PY - 2026
DA - 2026/09/22
JO - Phytotherapy Research
DO - 10.1002/ptr.70457
UR - https://doi.org/10.1002/ptr.70457
AB - Osteoporosis is a chronic bone disease marked by reduced density and increased fracture risk. Current treatments face limitations in safety, efficacy, and long‐term adherence, prompting interest in alternative therapies. Herbal medicine, with its bioactive compounds and historical use, offers potential for bone health support. This review explores the role of Chrysanthemum morifolium , Crocus sativus , Eriobotrya japonica , Ficus carica , Glycine max , Olea europaea , Salvia rosmarinus , and Zingiber officinale in preventing and managing osteoporosis. Relevant studies were identified through comprehensive searches of Google Scholar, PubMed, Scopus, and Web of Science, without time restriction up to October 2025. Included literature encompassed in vitro experiments, in vivo animal models, and clinical trials investigating herbal interventions targeting bone loss and osteoporosis‐related mechanisms. The reviewed botanicals modulate key molecular pathways involved in bone remodeling, including RANKL/NFATc1, MAPKs, NF‐κB, Sirt1, Nrf2, BMP/Smad, Wnt/β‐catenin, and XPO5–microRNA axes. Their bioactive constituents exert antioxidant, anti‐inflammatory, anti‐apoptotic, anti‐senescent, and hormone‐modulating effects, collectively promoting osteoblast differentiation and suppressing osteoclastogenesis. Several agents, such as crocin, safranal, and ursolic acid, demonstrated dual‐action profiles and favorable safety in preclinical models, with emerging evidence supporting their immunomodulatory and angiogenic roles. Herbal therapeutics offer a multi‐targeted, biologically harmonious approach to osteoporosis management. This review provides a mechanistic synthesis and translational framework for future research, highlighting their potential as adjunctive therapies, especially in aging populations. Standardization, clinical validation, and interdisciplinary collaboration are essential to advance these botanicals from bench to bedside.
SN - 0951-418X
SN - 1099-1573
ER -